We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

357 hedge funds and large institutions have $8.94B invested in Jazz Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 126 increasing their positions, 120 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 36

25% more funds holding in top 10

Funds holding in top 10: 1215 (+3)

10% more funds holding

Funds holding: 325357 (+32)

5% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 120

4% more capital invested

Capital invested by funds: $8.58B → $8.94B (+$355M)

27% less call options, than puts

Call options by funds: $86.4M | Put options by funds: $119M

Holders
357
Holders Change
+32
Holders Change %
+9.85%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.4%
New
76
Increased
126
Reduced
120
Closed
36
Calls
$86.4M
Puts
$119M
Net Calls
-$32.4M
Net Calls Change
+$92.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
26
Norges Bank
Norway
$57.4M +$7.89M +47,558 +16%
BG
27
BlackRock Group
United Kingdom
$55.3M +$29.1M +175,527 +108%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$52.5M +$1.59M +9,602 +3%
TA
29
Teachers Advisors
New York
$49.4M +$20.9M +126,082 +72%
RIM
30
RS Investment Management
California
$47.1M -$358K -2,154 -0.7%
First Trust Advisors
31
First Trust Advisors
Illinois
$43.4M -$2.46M -14,827 -5%
CM
32
Churchill Management
California
$43.2M -$10.9M -65,879 -20%
ACM
33
Apex Capital Management
Ohio
$43.2M +$2.15M +12,946 +5%
AAMU
34
Amundi Asset Management US
Massachusetts
$41.6M -$9.49M -57,161 -18%
AAP
35
Ardsley Advisory Partners
Connecticut
$41.4M -$2.49M -15,000 -6%
CCI
36
Columbus Circle Investors
$41.2M -$7.11M -42,837 -15%
Bank of America
37
Bank of America
North Carolina
$39M -$5.99M -36,089 -13%
Ninety One (UK)
38
Ninety One (UK)
United Kingdom
$38.2M -$1.23M -7,403 -3%
Deutsche Bank
39
Deutsche Bank
Germany
$37.9M +$11.6M +70,044 +43%
RIM
40
Rainier Investment Management
Washington
$33.6M -$3.36M -20,260 -9%
TCM
41
Tekla Capital Management
Massachusetts
$33M +$4.66M +28,100 +16%
Axa
42
Axa
France
$29M +$263K +1,586 +0.9%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$28.4M +$867K +5,225 +3%
CS
44
Credit Suisse
Switzerland
$27.7M +$8.86M +53,401 +46%
BGIM
45
Brandywine Global Investment Management
Pennsylvania
$27.1M +$27.5M +165,775 New
UBS Group
46
UBS Group
Switzerland
$27.1M +$27.5M +165,558 New
OAM
47
Origin Asset Management
United Kingdom
$26.3M -$3.77M -22,701 -12%
BSA
48
Braun Stacey Associates
New York
$23.4M -$1.92M -11,540 -7%
PC
49
Polar Capital
United Kingdom
$22.7M +$10M +60,294 +77%
FAM
50
Fred Alger Management
New York
$22.5M -$2.33M -14,017 -9%

JAZZ Hedge Fund Activity: Q4 2014 in Review

357 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2014, worth a combined $8.94B — up 4.1% from $8.58B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 36 closed out — a net gain of 40 holders — while 126 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $71.4M. The largest seller was Wells Fargo, cutting an estimated $119M.

  • 357 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2014, up from 325 in Q3 2014.
  • Funds reported $8.94B of Jazz Pharmaceuticals stock for Q4 2014, up 4.1% quarter-over-quarter.
  • 76 funds opened new Jazz Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +40 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2014 was American Century Companies, an estimated $71.4M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2014 was Wells Fargo, an estimated $119M sold.

Based on aggregated 13F filings for Q4 2014.